Skip to content

CRN welcomes FDA’s proposal on drug preclusion

Rule would allow lawful marketing of NAC in supplements

WASHINGTON — The Council for Responsible Nutrition (CRN) has welcomed a proposal by the U.S. Food and Drug Administration (FDA) that would allow N-acetyl-L-cysteine (NAC) to be lawfully marketed in dietary supplements.

But CRN expressed disappointment that the proposal falls short of providing a process for other ingredients to be added to the list and raises questions about the agency’s drug preclusion framework.

"We welcome FDA's proposal to establish a regulatory pathway that would provide certainty for NAC," said Steve Mister, president and CEO of CRN. "But without a clear framework for how other ingredients can be added, the industry is left with many of the same uncertainties that have persisted for years. 

The proposed rule demonstrates the need for corrective legislation like the Dietary Supplement Innovation Act to provide a clear roadmap for drug preclusion, according to CRN.

"Drug preclusion is essentially a convergence of pharmaceutical and supplement economic interests; safety is only one factor in the decision,” Mister said. “We need clear, transparent and predictable criteria for when drug preclusion applies that provide certainty not just for NAC, but for dietary supplement innovation more broadly."

CRN has asked the agency to reconsider its interpretation of the drug preclusion provision under Section 201(ff)(3)(B) of the Federal Food, Drug, and Cosmetic Act. Among other requests, CRN called on FDA to establish clear criteria for exercising its statutory authority to permit certain ingredients to be marketed as dietary supplements even when they might otherwise be subject to drug preclusion.

Although the FDA last year denied a CRN petition filed, the newly proposed rule reflects some of the concerns the council has consistently raised regarding the need for a more predictable approach to drug preclusion

"FDA has opened the door for other ingredients to be considered but it has not explained how manufacturers can walk through it," Mister said.

CRN emphasized that broader reform must address fundamental questions regarding when drug preclusion applies, including FDA's reliance on confidential investigational new drug application dates, the meaning of substantial clinical investigations, and the circumstances under which pharmaceutical research should preclude an ingredient from the dietary supplement marketplace.

Drug preclusion decisions must account for the competing interests of pharmaceutical and dietary supplement manufacturers, including whether products differ in their routes of administration, dosage levels and intended uses. These distinctions are essential to determining whether the products genuinely compete in the marketplace and whether excluding an ingredient from dietary supplements serves the purposes of the law.

CRN reiterates its support for the Dietary Supplement Innovation Act, H.R. 10336, introduced by Rep. Diana Harshbarger, which would modernize the statutory framework, establish more transparent standards and preserve appropriate incentives for pharmaceutical innovation without unnecessarily restricting access to dietary supplements.

Latest